The antihypertensive drug Valsartan and amlodipine tablets developed by CSPC PHARMA (01093) have been approved to conduct clinical trials.

16:53 20/09/2024

Shiyao Group (01093) announced that the valsartan and amlodipine maleate tablets developed by the group have been approved by the People's Republic of China.

CSPC PHARMA (01093) announced that the group's developed combination of Valsartan and Amlodipine Maleate tablets has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is the world's first approved clinical formulation composed of Valsartan and Amlodipine Maleate. Valsartan and Amlodipine are angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB) respectively, both of which are well-defined antihypertensive drugs with rich experience in combination therapy in clinical practice. The approved clinical indication for this product is mild to moderate essential hypertension that cannot be effectively controlled by monotherapy. Compared to monotherapy products for hypertension, this product has clinical development value in terms of effectiveness and safety.

HK Stock Market Move | Biocytogen Pharmaceuticals-B(02315) rises by more than 5%, main business prosperity drives high income growth, institutions are optimistic about the company's long-term growth potential.

HK Stock Market Move | Some coal stocks have further expanded their gains, Indonesian mineral traders have temporarily suspended the export of spot coal, institutions are optimistic about overseas layout coal companies.

A-share market closing review | The market rebounded in the last two days of trading, with the Shanghai Composite Index closing up by 0.85% to surpass the 4100 points mark. The photovoltaic sector experienced an overall surge.